Development and characterization of Gal KO porcine bone marrow‐derived mesenchymal stem cells
- 3 November 2021
- journal article
- research article
- Published by Wiley in Xenotransplantation
- Vol. 28 (6) , e12717
Abstract
Background: We demonstrated that neonatal porcine bone marrow‐derived mesenchymal stem cell (npBM‐MSCs) could improve a critical ischemic limb disease in rat model more efficiently compared with human MSCs. However, since porcine MSC presents galactosyl‐alpha 1,3‐galactose antigen (Gal antigen), MSC could be eliminated by the xenogeneic rejection. Recently, we established Gal knockout (KO) pigs by a technique of the electroporation of the CRISPR/Cas9 system into vitro‐fertilized zygotes. In this study, we hypothesized that MSC from the established Gal KO pigs could further improve the efficacy. Before examining the hypothesis, in this study, we have established and characterized bone marrow‐derived MSC from the Gal KO adult pigs (apBM‐MSCs).Methods: Mononuclear cells (MNCs) were isolated from bone marrow cells of both Gal KO adult pigs and wild‐type (WT) adult pigs. MNCs were further manipulated to create Gal KO apBM‐MSCs and WT apBM‐MSCs. Both MSCs were assessed by their surface markers, the capability of differentiation into adipocytes, osteocytes and chondrocytes, grow speed and colony‐forming assay. To assess the efficacy of Gal KO apBM‐MSCs, angiogenesis‐related genes and immunosuppression‐related genes were assessed by cytokine stimulation.Results: Gal KO apBM‐MSC showed no Gal antigen on their cell surfaces. Both Gal KO apBM‐MSCs and WT apBM‐MSCs, presented little or no negative surface markers of MSCs, while they presented positive surface markers of MSCs. Furthermore, Gal KO apBM‐MSCs were able to differentiate into adipocytes, osteocytes, and chondrocytes as well as WT apBM‐MSCs. There was no difference in doubling time between Gal KO apBM‐MSCs and WT apBM‐MSCs. Interestingly, the colony‐forming efficiency of Gal KO apBM‐MSCs was about half that of WT apBM‐MSC. However, angiogenesis and immunosuppression‐related genes were equally upregulated in both Gal KO apBM‐MSCs and WT apBM‐MSCs by cytokine stimulation.Conclusion: We created and characterized Gal KO apBM‐MSCs which showed similar characteristics and cytokine‐induced gene upregulation to the WT apBM‐MSCs.Keywords
This publication has 12 references indexed in Scilit:
- Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditionsCytotherapy, 2020
- Efficient generation of GGTA1-deficient pigs by electroporation of the CRISPR/Cas9 system into in vitro-fertilized zygotesBMC Biotechnology, 2020
- A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cellsRegenerative Therapy, 2020
- Development and characterization of novel clinical grade neonatal porcine bone marrow‐derived mesenchymal stem cellsXenotransplantation, 2019
- The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cellsStem Cell Research & Therapy, 2018
- Clinical-scale expansion of mesenchymal stromal cells: a large banking experienceJournal of Translational Medicine, 2016
- First Approval of Regenerative Medical Products under the PMD Act in JapanCell Stem Cell, 2016
- The Potential Role of Genetically-Modified Pig Mesenchymal Stromal Cells in XenotransplantationStem Cell Reviews and Reports, 2013
- α1,3Galactosyltransferase knockout pigs produce the natural anti‐Gal antibody and simulate the evolutionary appearance of this antibody in primatesXenotransplantation, 2013
- Is CD34 truly a negative marker for mesenchymal stromal cells?Cytotherapy, 2012